IN A PREVIOUS STUDY it was found that buprenorphine hydrochloride is a potent analgesic and that severe post-operative pain is relieved appreciably for at least six hours by 0.4 mg or less. 1 This confirmed impressions gained from studies on animals and man currently in progress abroad. 2'3
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72 N =40 >5hr: 7 >12hr: 4 *1 patient was not medicated after the anlpoule was opened because, on reconsideration, the amount of pain was overestimated. who appeared to be asleep during the study period were aroused for each interview. 5 Other observations recorded included auscultatory blood pressure, pulse rate, respiratory rate, de~ree of sedation (1 ---= alert; 2 = mildly drowsy; 3 = moderately drowsy; and 4 = asleep ) and side effects ( "is anything bothering you?") including objective signs such as miosis, retching, vomiting, and sweating.
All data derived from interviews were recorded along with notes of other observations and subsequently analyzed statistically, s,9
The large majority of the patients in this study were premedicated with diazepam and atropine, received enflurane-nitrous oxide anaesthesia following induction with thiopentone and pancuronium and had mechanically controlled pulmonary ventilation. At the end of the operation, residual effect of the muscle relaxant was reversed with atropine and neostigmine (1:2) prior to extubation.
RESULTS
Using analyses of variance or chi-square tests, the four treatment groups were found to be comparable with respect to the demographic variables -age, sex, weight, height, and race. Over-all, for the 159 patients who received the drug in the test, 118 were female and 147 were caucasian. The average height and weight was 165 cms and 70 kgs, respectively. The average age was 45 years with a range of 18 to 85 ( see Table I ).
To determine comparability of treatment groups at baseline, an analysis of variance was performed on the pre-drug pain intensity scores. Pain was severe in 96 per cent of all patients and in at least 92 per cent of each group, indicating that the groups were comparable. The average pain reduction over three and six hours (AVPRED 3, AVPRED 6, AVPREL 3, AVPREL 6) were analyzed as they were in the report of the open study. 1 An additional parameter, R-Time, was also analyzed. R-Time is the duration of relief as measured by the time interval between administration of test drug and the administration of the next analgesic. If no analgesic was given within 12 hours, a value of 13 was assigned for purposes of analysis. To compare the four treatment groups, each of these five parameters were analyzed by an analysis of variance with blocking on the pre-drug pain severity. The mean response for each treatment group was adjusted for differences in the pre-drug pain intensity. Paired comparisons of the four treatment groups were performed on the adjusted means, using two-sided t-tests.
MAX PAIN
The comparisons show that there were significant differences among the four treatment groups for all five parameters. The pair comparisons showed that in all cases, the 5 mg dose of morphine was inferior to the other three doses.
The comparison of buprenorphine 0.4 mg with morphine 10 mg was statistically significant at the P -0.05 level for the average pain relief over six hours and approached statistical significance for the average pain reduction over six hours. In both instances, buprenorphine 0.4 mg was favored over morphine 10 mg. ( Figures 1-4 . )
The mean duration of relief was 5.0 and 6.3 hours for buprenorphine (0.9. and 0.4 mg respectively) and 3.1 and 5.1 hours for morphine (5 and 10 mg respectively). The median duration of relief was found to be 4.2 and 4.8 hours for buprenorphine Over-all, both doses of buprenorphine were superior to morphine 5 mg and at least as good as morphine 10 mg. Both doses of buprenorphine appeared to produce very similar responses.
Since both doses of buprenorphine appeared so similar, potency estimation was somewhat difficult. Graphical display of the adjusted means plotted against logdose suggested that between 0.11 and 0.18 mg of buprenorphine is equivalent to morphine 10 mg. In other words, buprenorphine is at least 50 times more potent than morphine.
In the assessment of sedation and vital sign data, nothing extraordinary was seen. Buprenorphine appeared to produce more sedation than morphine but the degree of sedation was not inordinately high. The buprenorphine average sedation was only one-fourth of the way from "alert" to "mildly drowsy." No undesirable effects were seen in respiratory rate or blood pressure. Both drugs appeared to decrease the pulse rate somewhat by one hour. The incidence of side effects was essentially the same for both drugs ( 11 per cent for buprenorphine and 12 per cent for morphine). Drowsiness was the only frequent side effect. Nausea and/or vomiting occurred in seven patients who received morphine and in four patients who received buprenorphine.
The Duncan Multiplc comparisons on the raw means for AVPRED 3, AVPREL 3, AVPREL 6 and R-Time parameters confirmed that buprenorphine 0.2 mg and Assessing pain intensity has troubled the clinical investigator for many years. 4-7 It is, therefore, important to test analgesics on patients in whom there is no reasonable doubt that the person has a good objective reason for complaining of pain. Such is the case almost invariably after elective abdominal surgery. 1~
Relief of pain by drugs is usually somewhat easier to assess both objectively and subjectively, but one must still depend primarily on the patient's statements at interview for valid use of current scoring systems. ~,5 Long interviews and word association tests are inappropriate for evaluating pain medication in the postoperative patient. 13,]4,a5
Since the four groups obtained in this study were statistically comparable in all respects, the analysis of the pain intensity and pain relief scores could render reliable data. Employing recognized statistical tests and from examination of the graphed score data it appears that valid conclusions may be drawn, viz: that buprenorphine is at least 50 times more potent than morphine and that its analgesic activity is substantially longer in duration than morphine.
In other respects buprenorphine and morphine arc probably quite similar (drowsiness, miosis, nausea) and cannot be differentiated easily. Neither analgesic caused appreciable changes in cardiorespiratory function.
Since buprenorphine hydrochloride can be synthesized and appears to have a low propensity to addiction and tolerance, it may be a useful substitute for morphine and its analgesic analogues. Buprenorphine, therefore, deserves extensive further evaluation.
SUMMARY AND CONCLUSIONS
In a double-blind, random assignment study of four groups of 40 patients, relief of severe pain with buprenorphine hydrochloride 0.2 mg or 0.4 mg was evaluated and compared with morphine sulphate 5 or 10 mg. Evaluations included pain intensity, pain relief, sedation and other effects for up to 12 hours after drug administration, following recovery of wakefulness from anaesthesia for major abdominal surgery. Analyses of five parameters showed that the four groups were statistically comparable and that buprenorphine hydrochloride is at least 50 times more potent than morphine sulphate and has a substantially longer duration of analgesic action. Further clinical evaluation is, therefore, recommended.
R~SUM~
Le chlorure de buprenorphine a des doses de 0.2 et de 0.4 mga 6t6 compar6e la morphine ~ des doses de 5 et de 10 nag, ceci apr6s 6veil de l'anesth6sie et suivant une chirurgie abdominale majeure. L'intensit6 de la douleur, son soulagement et la s6dation produite, ai~si que les autres effets observ6s, ceci dans les 12 heures suivant l'administration, ont 6t6 ~valu6s.
Cette ~tude ~ double insu, portant sur une population volontaire de 160 rnalades, a permis de former quatre groupes au hasard, pour fins de comparaison des agents et des doses administrdes. L'analyse de nos r~sultats d~montre que (1) nos quatre groupes ~taient statistiquement comparables, (2) que le chlorure de buprenorphine est au moins 50 fois plus puissant que la morphine et (3) que son action est substantiellement plus longue.
On rccommande la poursuite de son ~valuation clinique.
